ERAS vs. VERV, BDTX, LYEL, NUVB, BCYC, TARO, AKRO, SDGR, DVAX, and MORF
Should you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Verve Therapeutics (VERV), Black Diamond Therapeutics (BDTX), Lyell Immunopharma (LYEL), Nuvation Bio (NUVB), Bicycle Therapeutics (BCYC), Taro Pharmaceutical Industries (TARO), Akero Therapeutics (AKRO), Schrödinger (SDGR), Dynavax Technologies (DVAX), and Morphic (MORF). These companies are all part of the "medical" sector.
Erasca (NASDAQ:ERAS) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
In the previous week, Verve Therapeutics had 2 more articles in the media than Erasca. MarketBeat recorded 2 mentions for Verve Therapeutics and 0 mentions for Erasca. Erasca's average media sentiment score of 1.00 beat Verve Therapeutics' score of 0.13 indicating that Erasca is being referred to more favorably in the media.
Erasca and Verve Therapeutics both received 18 outperform votes by MarketBeat users. However, 64.29% of users gave Erasca an outperform vote while only 46.15% of users gave Verve Therapeutics an outperform vote.
Erasca presently has a consensus price target of $6.00, suggesting a potential upside of 152.10%. Verve Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 527.38%. Given Verve Therapeutics' higher probable upside, analysts clearly believe Verve Therapeutics is more favorable than Erasca.
67.8% of Erasca shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 21.5% of Erasca shares are held by insiders. Comparatively, 19.3% of Verve Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Erasca has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.
Erasca has a net margin of 0.00% compared to Verve Therapeutics' net margin of -1,226.51%. Verve Therapeutics' return on equity of -37.35% beat Erasca's return on equity.
Erasca has higher earnings, but lower revenue than Verve Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Verve Therapeutics beats Erasca on 9 of the 16 factors compared between the two stocks.
Get Erasca News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
